Pasithea Therapeutics Corp.

Healthcare · Biotechnology · United States

Last price 0.3696 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 12.35M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary scle...